May 6, 2015 by Brian Orelli, PhDbluebird bio Plans to Sing in JuneDuring its first-quarter earnings release, bluebird bio discloses plans to present data at the European Hematology Association meeting in June.
May 5, 2015 by Brian Orelli, PhDWaiting for Profitability at Genomic Health, Inc.The first quarter produced a loss, as expected, but the growth should set up Genomic Health for a fourth-quarter profit if reimbursement comes to fruition.
May 5, 2015 by Brian Orelli, PhDIt's Partners and Pipeline Before Bean Counting at Isis Pharmaceuticals, Inc.Isis Pharmaceuticals highlights its new partnerships while continuing to shrug off sales of its approved drug, Kynamro.
May 1, 2015 by Brian Orelli, PhDGilead Sciences, Inc. Earnings: Hepatitis C Market by the NumbersGilead posts a solid quarter boosted by its hepatitis C franchise.
May 1, 2015 by Brian Orelli, PhDWaiting for Exelixis, Inc.'s Meteor to LandData from the biotech's kidney cancer trial won't be available until late in the second quarter or potentially even later.
May 1, 2015 by Brian Orelli, PhDHot Issues on BioMarin Pharmaceutical Inc. Earnings Conference CallVimizim steals the show as investors wait for an FDA decision on drisapersen
Apr 30, 2015 by Brian Orelli, PhDSeattle Genetics, Inc. Posts Solid First-Quarter Revenue, Raises Expense GuidanceNot exactly the beat-and-raise investors were looking for.
Apr 30, 2015 by Brian Orelli, PhDCelgene Corporation Hits a Triple, Yet Investors BooDespite 20% revenue growth, high expectations hurt Celgene.
Apr 30, 2015 by Brian Orelli, PhDTeva Pharmaceutical Industries Ltd Posts Solid Quarter, Stays Mum on MylanDespite flat revenue, profits increased substantially.
Apr 29, 2015 by Brian Orelli, PhDVertex Pharmaceuticals Incorporated: Waiting to ExhaleEarnings are important, but the approval of Orkambi towers over Vertex's long-term potential.
Apr 29, 2015 by Brian Orelli, PhD3 Things to Watch as BioMarin Pharmaceutical Inc. Reports EarningsFocus will be on the potential approval of drisapersen, but don't forget about BioMarin's other drugs.
Apr 29, 2015 by Brian Orelli, PhD3 Things to Watch as Seattle Genetics, Inc. Reports EarningsAdcetris sales, potential label expansion, and an update on the pipeline will all be important.
Apr 28, 2015 by Brian Orelli, PhDInvestors Put IDEXX Laboratories Inc. in the DoghouseA stronger dollar and slow growth of its rapid assay products make for a rough first quarter.
Apr 26, 2015 by Brian Orelli, PhD, Sean Williams, and Todd CampbellWhy Healthcare is the Best Sector For Your MoneyOur experts weigh in.
Apr 24, 2015 by Brian Orelli, PhDBiogen Inc Earnings: Tecfidera Turbulance8 reasons that Tecfidera sales declined quarter over quarter.
Apr 24, 2015 by Brian Orelli, PhDMixed Bag for ImmunoGen Inc.Pipeline progressing but with some setbacks mixed in.
Apr 24, 2015 by Brian Orelli, PhDArena Pharmaceuticals Inc.'s Plan to Win the Obesity Drug WarBuilding a better mousetrap.
Apr 23, 2015 by Brian Orelli, PhDBaxter International Inc.: Where a Decline Is a WinOn the eve of its breakup, Baxter beats guidance of falling earnings.
Apr 22, 2015 by Brian Orelli, PhDAdding Up Baby Steps at Natus Medical Inc.Small increases in revenue plus small increases in margins result in decent earnings growth.
Apr 21, 2015 by Brian Orelli, PhDA Tale of Two Cities at Intuitive Surgical, Inc.Higher revenue didn't translate into higher earnings.
